Analyst Daniel Brennan of TD Cowen maintained a Buy rating on Revvity, retaining the price target of $126.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan’s rating is based on a combination of factors, despite some setbacks faced by Revvity. The company’s overall business performance remains strong, with approximately 94% of its operations on track. Although the ImmunoDx segment in China experienced pressure due to changes in hospital payment reforms, this issue is not considered to alter the overall investment thesis significantly.
Despite the challenges in China, Revvity’s organic growth and earnings per share (EPS) have shown resilience, outperforming expectations in the second quarter. The company’s free cash flow remains robust, and management’s commitment to cost controls is expected to drive EBIT expansion by more than 100 basis points in 2026. These factors, coupled with an attractive entry point created by the recent stock pullback, underpin Brennan’s Buy rating.
In another report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $129.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RVTY in relation to earlier this year.